Skye Bioscience Inc (SKYE)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 09-2019 | 06-2019 | 03-2019 | 12-2018 | 09-2018 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -3,800 | 1,131 | -14,774 | -19,194 | -12,972 |
| Depreciation Amortization | 440 | 246 | 57 | 60 | 36 |
| Accounts payable and accrued liabilities | 191 | 58 | 153 | -85 | -40 |
| Other Working Capital | 23 | 71 | -29 | 100 | 104 |
| Other Operating Activity | -1,379 | -4,542 | 13,162 | 15,176 | 9,944 |
| Operating Cash Flow | $-4,525 | $-3,036 | $-1,431 | $-3,943 | $-2,929 |
| Cash Flows From Investing Activities | |||||
| PPE Investments | N/A | N/A | N/A | -4 | -4 |
| Investing Cash Flow | $N/A | $N/A | $N/A | $-4 | $-4 |
| Cash Flows From Financing Activities | |||||
| Change In Short Term Borrowing | 3,991 | 3,991 | 3,991 | 2,346 | 400 |
| Common Stock Issued | N/A | N/A | N/A | 3,195 | 3,332 |
| Financing Cash Flow | $3,991 | $3,991 | $3,991 | $5,541 | $3,732 |
| Beginning Cash Position | 1,858 | 1,858 | 1,858 | 264 | 264 |
| End Cash Position | 1,324 | 2,812 | 4,418 | 1,858 | 1,063 |
| Net Cash Flow | $-534 | $955 | $2,560 | $1,594 | $799 |
| Free Cash Flow | |||||
| Operating Cash Flow | -4,525 | -3,036 | -1,431 | -3,943 | -2,929 |
| Capital Expenditure | N/A | N/A | N/A | -4 | -4 |
| Free Cash Flow | -4,525 | -3,036 | -1,431 | -3,947 | -2,933 |